Mastocytosis Registry of Zurich
Part of Cancer, Immune system & allergy clinical trials.
This study is a registry (a simple data collection) for people with mastocytosis or hypertryptasemia who are treated at the University Hospital of Zurich. It aims to gather information to better understand these conditions and improve care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have been diagnosed with mastocytosis or high tryptase levels (hypertryptasemia)
- You are being treated at the University Hospital of Zurich
- You are willing to sign a consent form to join the study
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at what causes mast cells to grow too much in people with mastocytosis. It may help researchers find better ways to diagnose or treat this condition. You can take part in person or by telehealth.
This study looks at IgE, a protein involved in allergic reactions, to better understand its role in different immune-related diseases. It aims to find out how different forms of IgE relate to health and disease, which may help improve diagnosis or treatment.
This study builds a “registry,” which is a secure list of people with rare diseases or suspected rare diseases in Switzerland. It helps researchers better understand these conditions over time and improve care.
This trial is a registry that collects health information from people with amyloidosis, including cases where the heart may be involved. Sharing your medical details can help researchers learn how this condition affects patients and may guide future care.
This study is a patient registry that collects health information from people diagnosed with a neuromuscular disorder in Switzerland. It helps researchers better understand these conditions and how they vary from person to person.
This registry enrolls people with a confirmed diagnosis of multiple sclerosis (MS) who are age 18 or older and live in Switzerland (or receive their MS care there). It helps researchers better understand MS in the Swiss population and may improve future studies and care.
Hear when a new Mastocytosis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.